Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications

NCT02320721 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1014

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Insulin Glargine (HOE901 - U300)
DRUG: Insulin Glargine (HOE901 - U100)
DRUG: Background therapy

Sponsor

Sanofi